Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Akari Therapeutics (CLA1) Stock Price & Analysis

CLA1 Stock Chart & Stats

€0.06€0.00(0.00%)
At close: 5:30 PM GMT+1
EUR 250EUR 50021 Sep10 Jul13 Oct28 Mar
Day’s Range
EUR 0.06 - EUR 0.16
52-Week Range
EUR 0.06 - EUR 22.80
Previous Close
EUR 0.06
Volume
0
Average Volume (3M)
0
Market Cap
EUR 12.87M
Enterprise Value
EUR 11.29M
Total Cash (Recent Filing)
EUR 7.69M
Total Debt (Recent Filing)
EUR 693.00K
Price to Earnings (P/E)
―
Beta
1.30
Next Earnings
Apr 21, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Minimal leverage reduces fixed financial obligations and leaves less exposure to interest or refinancing pressure. This gives Akari greater balance-sheet flexibility while it advances its development programs, although it does not remove the need to fund ongoing operations.

Specialized Development Focus

A focused strategy around autoimmune and inflammatory diseases, complement biology, and antibody-based approaches gives the company a defined scientific direction. Concentrating limited resources on these pathways may support deeper expertise and clearer prioritization across its pipeline.

Talent Incentive Capacity

Increasing the equity incentive pool can help a small, research-led biotechnology company attract and retain specialized employees needed to advance its programs. Stronger hiring and retention capacity may support execution over the next several quarters, subject to the associated dilution.

Bears Say

No Revenue

Akari has not yet established commercial revenue, so its operating model remains dependent on successfully advancing investigational programs before generating sales. The absence of revenue limits internally funded growth and leaves future financial performance tied to development progress and eventual commercialization.

Widening Losses

The substantial increase in net losses indicates deteriorating earnings power and a higher cost burden while the company remains pre-revenue. Persistent losses can accelerate consumption of the capital base, increase financing needs, and make it harder to sustain development without additional funding.

Cash Burn And Dilution

Negative operating and free cash flow show that Akari cannot currently fund its activities from operations. Combined with a shrinking equity base and the expanded share incentive pool, continued funding needs may pressure shareholders through further capital raises or equity-based compensation.

Akari Therapeutics News

CLA1 FAQ

What was Akari Therapeutics’s price range in the past 12 months?
Akari Therapeutics lowest stock price was €0.06 and its highest was €22.80 in the past 12 months.
What is Akari Therapeutics’s market cap?
Akari Therapeutics’s market cap is €12.87M.
When is Akari Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Akari Therapeutics’s earnings last quarter?
Akari Therapeutics released its earnings results on Aug 13, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.917 by €0.917.
Is Akari Therapeutics overvalued?
According to Wall Street analysts Akari Therapeutics’s price is currently Undervalued.
Does Akari Therapeutics pay dividends?
Akari Therapeutics does not currently pay dividends.
What is Akari Therapeutics’s EPS estimate?
Akari Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Akari Therapeutics have?
Akari Therapeutics has 2,285,165 shares outstanding.
What happened to Akari Therapeutics’s price movement after its last earnings report?
Akari Therapeutics reported an EPS of €0 in its last earnings report, beating expectations of -€0.917. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Akari Therapeutics?
Currently, no hedge funds are holding shares in DE:CLA1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology